Yüksel Ürün
@yukselurun.bsky.social
Medical Oncologist 🔬 @AnkaraUni 🎓 Advocate for #Diversity & #Equity 🌟 Genitourinary Cancer
Some illnesses touch the body, some touch the quiet place in the soul.
Healing often begins there…
Healing often begins there…
November 27, 2025 at 8:39 PM
Some illnesses touch the body, some touch the quiet place in the soul.
Healing often begins there…
Healing often begins there…
Hastalarımıza gerçeği anlatmak.
Ne korku satmak, ne de sahte umut vermek.
Medya, veriyi dürüst anlattığında güç katar. Ama çarpıtılmış grafikler, abartılmış başlıklar, seçilmiş veriler…
Korku yaratır. Umudu kirletir.
Gerçeği savunmak, hastalarımızı korumaktır. Veri konuşsun, biz dinleyelim.
Ne korku satmak, ne de sahte umut vermek.
Medya, veriyi dürüst anlattığında güç katar. Ama çarpıtılmış grafikler, abartılmış başlıklar, seçilmiş veriler…
Korku yaratır. Umudu kirletir.
Gerçeği savunmak, hastalarımızı korumaktır. Veri konuşsun, biz dinleyelim.
October 10, 2025 at 6:37 PM
Hastalarımıza gerçeği anlatmak.
Ne korku satmak, ne de sahte umut vermek.
Medya, veriyi dürüst anlattığında güç katar. Ama çarpıtılmış grafikler, abartılmış başlıklar, seçilmiş veriler…
Korku yaratır. Umudu kirletir.
Gerçeği savunmak, hastalarımızı korumaktır. Veri konuşsun, biz dinleyelim.
Ne korku satmak, ne de sahte umut vermek.
Medya, veriyi dürüst anlattığında güç katar. Ama çarpıtılmış grafikler, abartılmış başlıklar, seçilmiş veriler…
Korku yaratır. Umudu kirletir.
Gerçeği savunmak, hastalarımızı korumaktır. Veri konuşsun, biz dinleyelim.
Cancer care often forgets those at the edges: teens, elders, people with rare cancers. Their needs don’t fit the standard path. Fertility, intimacy, body image deserve the same care as the tumor.
@oncoalert.bsky.social @oncoassist.bsky.social
@oncoalert.bsky.social @oncoassist.bsky.social
October 7, 2025 at 6:00 PM
Cancer care often forgets those at the edges: teens, elders, people with rare cancers. Their needs don’t fit the standard path. Fertility, intimacy, body image deserve the same care as the tumor.
@oncoalert.bsky.social @oncoassist.bsky.social
@oncoalert.bsky.social @oncoassist.bsky.social
Proud of our rising star Coşkun and all colleagues. This meta-analysis on PARP inhibitors and thrombosis risk asks the right question for patients.
@oncoalert.bsky.social @myesmo.bsky.social @apccc.bsky.social @drchoueiri.bsky.social @neerajagarwal.bsky.social
@oncoalert.bsky.social @myesmo.bsky.social @apccc.bsky.social @drchoueiri.bsky.social @neerajagarwal.bsky.social
September 30, 2025 at 5:00 PM
Proud of our rising star Coşkun and all colleagues. This meta-analysis on PARP inhibitors and thrombosis risk asks the right question for patients.
@oncoalert.bsky.social @myesmo.bsky.social @apccc.bsky.social @drchoueiri.bsky.social @neerajagarwal.bsky.social
@oncoalert.bsky.social @myesmo.bsky.social @apccc.bsky.social @drchoueiri.bsky.social @neerajagarwal.bsky.social
Global voices, shared hope.
Excited to join colleagues at VIRO 2025—working together for patients in renal cancer.
#OncoDaily #VIRO2025
@oncodaily.bsky.social
docs.google.com/forms/d/e/1F...
Excited to join colleagues at VIRO 2025—working together for patients in renal cancer.
#OncoDaily #VIRO2025
@oncodaily.bsky.social
docs.google.com/forms/d/e/1F...
September 8, 2025 at 2:22 PM
Global voices, shared hope.
Excited to join colleagues at VIRO 2025—working together for patients in renal cancer.
#OncoDaily #VIRO2025
@oncodaily.bsky.social
docs.google.com/forms/d/e/1F...
Excited to join colleagues at VIRO 2025—working together for patients in renal cancer.
#OncoDaily #VIRO2025
@oncodaily.bsky.social
docs.google.com/forms/d/e/1F...
Cancer vaccines: the next frontier is now.
From HBV & HPV to personalized mRNA shots
@oncoalert.bsky.social @oncoassist.bsky.social @ptarantinomd.bsky.social @drchoueiri.bsky.social @viveksubbiah.bsky.social
From HBV & HPV to personalized mRNA shots
@oncoalert.bsky.social @oncoassist.bsky.social @ptarantinomd.bsky.social @drchoueiri.bsky.social @viveksubbiah.bsky.social
July 2, 2025 at 6:25 AM
Cancer vaccines: the next frontier is now.
From HBV & HPV to personalized mRNA shots
@oncoalert.bsky.social @oncoassist.bsky.social @ptarantinomd.bsky.social @drchoueiri.bsky.social @viveksubbiah.bsky.social
From HBV & HPV to personalized mRNA shots
@oncoalert.bsky.social @oncoassist.bsky.social @ptarantinomd.bsky.social @drchoueiri.bsky.social @viveksubbiah.bsky.social
Take care of your kidneys, protect your life.
4 simple actions = less risk, better outcomes:
🚭 Quit smoking
⚖️ Stay at a healthy weight
🏃♀️ Be active, avoid trauma
💧 Drink water, skip alcohol
Because prevention is power
@oncoalert.bsky.social
@drchoueiri.bsky.social @kidneycan.bsky.social
4 simple actions = less risk, better outcomes:
🚭 Quit smoking
⚖️ Stay at a healthy weight
🏃♀️ Be active, avoid trauma
💧 Drink water, skip alcohol
Because prevention is power
@oncoalert.bsky.social
@drchoueiri.bsky.social @kidneycan.bsky.social
June 19, 2025 at 8:42 AM
Take care of your kidneys, protect your life.
4 simple actions = less risk, better outcomes:
🚭 Quit smoking
⚖️ Stay at a healthy weight
🏃♀️ Be active, avoid trauma
💧 Drink water, skip alcohol
Because prevention is power
@oncoalert.bsky.social
@drchoueiri.bsky.social @kidneycan.bsky.social
4 simple actions = less risk, better outcomes:
🚭 Quit smoking
⚖️ Stay at a healthy weight
🏃♀️ Be active, avoid trauma
💧 Drink water, skip alcohol
Because prevention is power
@oncoalert.bsky.social
@drchoueiri.bsky.social @kidneycan.bsky.social
🎗 Gerçek bilim bazen zor konuşur.
Herkes “mucize” ister, ama biz sabırla örülmüş gerçekleri anlatırız.
📌 Evet, süreç yorucu.
📌 Evet, sonuç her zaman adil değil.
Ama geçmişe göre çok daha iyiyiz.
Birçok tümörde, yıllar kazandıran tedaviler var artık
Herkes “mucize” ister, ama biz sabırla örülmüş gerçekleri anlatırız.
📌 Evet, süreç yorucu.
📌 Evet, sonuç her zaman adil değil.
Ama geçmişe göre çok daha iyiyiz.
Birçok tümörde, yıllar kazandıran tedaviler var artık
June 15, 2025 at 8:17 PM
🎗 Gerçek bilim bazen zor konuşur.
Herkes “mucize” ister, ama biz sabırla örülmüş gerçekleri anlatırız.
📌 Evet, süreç yorucu.
📌 Evet, sonuç her zaman adil değil.
Ama geçmişe göre çok daha iyiyiz.
Birçok tümörde, yıllar kazandıran tedaviler var artık
Herkes “mucize” ister, ama biz sabırla örülmüş gerçekleri anlatırız.
📌 Evet, süreç yorucu.
📌 Evet, sonuç her zaman adil değil.
Ama geçmişe göre çok daha iyiyiz.
Birçok tümörde, yıllar kazandıran tedaviler var artık
Bugünkü kelimemiz: Radikal Prostatektomi
🧬 Prostat kanseri tedavisinde sık kullanılan bu kelime, aslında ne demek?
👨⚕️ Prostat bezinin tamamen çıkarıldığı bir ameliyat. Genellikle erken evredeki hastalarda uygulanır.
🎯 Bilmek güç verir.
Takipte kalın, diğer terimleri de birlikte öğrenelim.
🧬 Prostat kanseri tedavisinde sık kullanılan bu kelime, aslında ne demek?
👨⚕️ Prostat bezinin tamamen çıkarıldığı bir ameliyat. Genellikle erken evredeki hastalarda uygulanır.
🎯 Bilmek güç verir.
Takipte kalın, diğer terimleri de birlikte öğrenelim.
June 10, 2025 at 3:05 PM
Bugünkü kelimemiz: Radikal Prostatektomi
🧬 Prostat kanseri tedavisinde sık kullanılan bu kelime, aslında ne demek?
👨⚕️ Prostat bezinin tamamen çıkarıldığı bir ameliyat. Genellikle erken evredeki hastalarda uygulanır.
🎯 Bilmek güç verir.
Takipte kalın, diğer terimleri de birlikte öğrenelim.
🧬 Prostat kanseri tedavisinde sık kullanılan bu kelime, aslında ne demek?
👨⚕️ Prostat bezinin tamamen çıkarıldığı bir ameliyat. Genellikle erken evredeki hastalarda uygulanır.
🎯 Bilmek güç verir.
Takipte kalın, diğer terimleri de birlikte öğrenelim.
🔬 Klinik Araştırma Nedir?
Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır.
Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar,
hem de gelecekte binlerce hayatın değişmesine katkı sağlar.
#science
Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır.
Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar,
hem de gelecekte binlerce hayatın değişmesine katkı sağlar.
#science
June 9, 2025 at 7:59 AM
🔬 Klinik Araştırma Nedir?
Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır.
Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar,
hem de gelecekte binlerce hayatın değişmesine katkı sağlar.
#science
Kanser gibi ciddi hastalıklar için daha etkili, daha güvenli tedaviler geliştirmek amacıyla yürütülen bilimsel çalışmalardır.
Her klinik araştırma; hem bugünün hastalarına yeni bir tedavi seçeneği sunar,
hem de gelecekte binlerce hayatın değişmesine katkı sağlar.
#science
Biyopsi = Şüpheli dokudan parça alıp mikroskopla incelemek.
Örneğin: “Mesanedeki kitlenin ne olduğunu anlamak için biyopsi yapıldı.”
🎯 Çünkü doğru tanı, doğru tedavinin ilk adımıdır.
Örneğin: “Mesanedeki kitlenin ne olduğunu anlamak için biyopsi yapıldı.”
🎯 Çünkü doğru tanı, doğru tedavinin ilk adımıdır.
June 7, 2025 at 2:34 PM
Biyopsi = Şüpheli dokudan parça alıp mikroskopla incelemek.
Örneğin: “Mesanedeki kitlenin ne olduğunu anlamak için biyopsi yapıldı.”
🎯 Çünkü doğru tanı, doğru tedavinin ilk adımıdır.
Örneğin: “Mesanedeki kitlenin ne olduğunu anlamak için biyopsi yapıldı.”
🎯 Çünkü doğru tanı, doğru tedavinin ilk adımıdır.
Every oncologist is a patient advocate.
Right treatment.
Right time.
For every patient.
#ASCO25 #Oncology #CancerCare #AccessMatters
@oncoalert.bsky.social @ascocancer.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social @oncbrothers.bsky.social
Right treatment.
Right time.
For every patient.
#ASCO25 #Oncology #CancerCare #AccessMatters
@oncoalert.bsky.social @ascocancer.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social @oncbrothers.bsky.social
June 4, 2025 at 1:13 PM
Every oncologist is a patient advocate.
Right treatment.
Right time.
For every patient.
#ASCO25 #Oncology #CancerCare #AccessMatters
@oncoalert.bsky.social @ascocancer.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social @oncbrothers.bsky.social
Right treatment.
Right time.
For every patient.
#ASCO25 #Oncology #CancerCare #AccessMatters
@oncoalert.bsky.social @ascocancer.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social @oncbrothers.bsky.social
Thrilled to share our new analysis from CheckMate 901!
🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS and OS.
➡️A new horizon for a distinct subgroup.
@uroweb.org @oncoalert.bsky.social @oncbrothers.bsky.social
🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS and OS.
➡️A new horizon for a distinct subgroup.
@uroweb.org @oncoalert.bsky.social @oncbrothers.bsky.social
May 21, 2025 at 5:41 AM
Thrilled to share our new analysis from CheckMate 901!
🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS and OS.
➡️A new horizon for a distinct subgroup.
@uroweb.org @oncoalert.bsky.social @oncbrothers.bsky.social
🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS and OS.
➡️A new horizon for a distinct subgroup.
@uroweb.org @oncoalert.bsky.social @oncbrothers.bsky.social
📢 Just in: Multivitamins after MI in diabetes?
🔬 In this RCT (n=1000), oral multivitamins didn't reduce CV events after MI in patients with diabetes.
🎯 35% event rate in both arms HR: 0.99
No benefit.
#Cardiology #Diabetes #RCT #JAMA
🔬 In this RCT (n=1000), oral multivitamins didn't reduce CV events after MI in patients with diabetes.
🎯 35% event rate in both arms HR: 0.99
No benefit.
#Cardiology #Diabetes #RCT #JAMA
May 6, 2025 at 1:41 PM
📢 Just in: Multivitamins after MI in diabetes?
🔬 In this RCT (n=1000), oral multivitamins didn't reduce CV events after MI in patients with diabetes.
🎯 35% event rate in both arms HR: 0.99
No benefit.
#Cardiology #Diabetes #RCT #JAMA
🔬 In this RCT (n=1000), oral multivitamins didn't reduce CV events after MI in patients with diabetes.
🎯 35% event rate in both arms HR: 0.99
No benefit.
#Cardiology #Diabetes #RCT #JAMA
New era for HER2-mutant lung cancer!
Zongertinib delivered a 71% response rate, 12.4 months median PFS!
No ILD reported.
Precision hitting its mark!
#LungCancer #Oncology #Targeted #cancerresearch
@nejm.org @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social
Zongertinib delivered a 71% response rate, 12.4 months median PFS!
No ILD reported.
Precision hitting its mark!
#LungCancer #Oncology #Targeted #cancerresearch
@nejm.org @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social
April 28, 2025 at 2:12 PM
New era for HER2-mutant lung cancer!
Zongertinib delivered a 71% response rate, 12.4 months median PFS!
No ILD reported.
Precision hitting its mark!
#LungCancer #Oncology #Targeted #cancerresearch
@nejm.org @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social
Zongertinib delivered a 71% response rate, 12.4 months median PFS!
No ILD reported.
Precision hitting its mark!
#LungCancer #Oncology #Targeted #cancerresearch
@nejm.org @oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social
Abstracts are out for #ASCO25!
5000+ studies. 5 Plenary game-changers.
@ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social
5000+ studies. 5 Plenary game-changers.
@ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social
April 23, 2025 at 4:21 PM
Abstracts are out for #ASCO25!
5000+ studies. 5 Plenary game-changers.
@ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social
5000+ studies. 5 Plenary game-changers.
@ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social
Thrilled to announce that our article has been selected as a Top Viewed Article in Cancer journal!
“Cancer-associated thrombosis and drug–drug interactions of antithrombotic/antineoplastic agents”
Thank you for reading, sharing making science matter @oncoalert.bsky.social @ascocancer.bsky.social
“Cancer-associated thrombosis and drug–drug interactions of antithrombotic/antineoplastic agents”
Thank you for reading, sharing making science matter @oncoalert.bsky.social @ascocancer.bsky.social
April 16, 2025 at 2:43 PM
Thrilled to announce that our article has been selected as a Top Viewed Article in Cancer journal!
“Cancer-associated thrombosis and drug–drug interactions of antithrombotic/antineoplastic agents”
Thank you for reading, sharing making science matter @oncoalert.bsky.social @ascocancer.bsky.social
“Cancer-associated thrombosis and drug–drug interactions of antithrombotic/antineoplastic agents”
Thank you for reading, sharing making science matter @oncoalert.bsky.social @ascocancer.bsky.social
What if we screened smarter, not just more?
In BARCODE1, men with high polygenic risk (top 10%) had MRI + biopsy—
40% had prostate cancer.
Over half needed treatment.
Most would’ve been missed by PSA alone.
Genetics is rewriting the rules.
@nejm.org @myesmo.bsky.social @oncoalert.bsky.social
In BARCODE1, men with high polygenic risk (top 10%) had MRI + biopsy—
40% had prostate cancer.
Over half needed treatment.
Most would’ve been missed by PSA alone.
Genetics is rewriting the rules.
@nejm.org @myesmo.bsky.social @oncoalert.bsky.social
April 10, 2025 at 5:30 AM
What if we screened smarter, not just more?
In BARCODE1, men with high polygenic risk (top 10%) had MRI + biopsy—
40% had prostate cancer.
Over half needed treatment.
Most would’ve been missed by PSA alone.
Genetics is rewriting the rules.
@nejm.org @myesmo.bsky.social @oncoalert.bsky.social
In BARCODE1, men with high polygenic risk (top 10%) had MRI + biopsy—
40% had prostate cancer.
Over half needed treatment.
Most would’ve been missed by PSA alone.
Genetics is rewriting the rules.
@nejm.org @myesmo.bsky.social @oncoalert.bsky.social
🧬 Genomic testing in childhood & young adult cancers:
🧬16–18% carry germline variants
🧬Somatic findings guide Dx in up to 95%
🧬Matched therapy? Often possible—rarely given
The science is ready. Let’s make care catch up.
@oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social
🧬16–18% carry germline variants
🧬Somatic findings guide Dx in up to 95%
🧬Matched therapy? Often possible—rarely given
The science is ready. Let’s make care catch up.
@oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social
April 8, 2025 at 9:08 PM
🧬 Genomic testing in childhood & young adult cancers:
🧬16–18% carry germline variants
🧬Somatic findings guide Dx in up to 95%
🧬Matched therapy? Often possible—rarely given
The science is ready. Let’s make care catch up.
@oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social
🧬16–18% carry germline variants
🧬Somatic findings guide Dx in up to 95%
🧬Matched therapy? Often possible—rarely given
The science is ready. Let’s make care catch up.
@oncoalert.bsky.social @viveksubbiah.bsky.social @ptarantinomd.bsky.social
🧬 Bigger isn’t always better—
In this randomized trial, a large 324-gene panel (F1CDX) identified more matched therapies vs. a smaller panel (51.6% vs 36.9%, +14.8%)
But… no survival benefit seen.
More targets ≠ better outcomes—yet.
@oncoalert.bsky.social
@viveksubbiah.bsky.social
rdcu.be/egWk9
In this randomized trial, a large 324-gene panel (F1CDX) identified more matched therapies vs. a smaller panel (51.6% vs 36.9%, +14.8%)
But… no survival benefit seen.
More targets ≠ better outcomes—yet.
@oncoalert.bsky.social
@viveksubbiah.bsky.social
rdcu.be/egWk9
April 8, 2025 at 9:06 PM
🧬 Bigger isn’t always better—
In this randomized trial, a large 324-gene panel (F1CDX) identified more matched therapies vs. a smaller panel (51.6% vs 36.9%, +14.8%)
But… no survival benefit seen.
More targets ≠ better outcomes—yet.
@oncoalert.bsky.social
@viveksubbiah.bsky.social
rdcu.be/egWk9
In this randomized trial, a large 324-gene panel (F1CDX) identified more matched therapies vs. a smaller panel (51.6% vs 36.9%, +14.8%)
But… no survival benefit seen.
More targets ≠ better outcomes—yet.
@oncoalert.bsky.social
@viveksubbiah.bsky.social
rdcu.be/egWk9
I’m always inspired by the brilliant minds on this list (and many others!) who generously share insights and push the field of oncology forward.
Grateful to @larvol for the inclusion. @ascocancer.bsky.social
Grateful to @larvol for the inclusion. @ascocancer.bsky.social
April 8, 2025 at 9:05 PM
I’m always inspired by the brilliant minds on this list (and many others!) who generously share insights and push the field of oncology forward.
Grateful to @larvol for the inclusion. @ascocancer.bsky.social
Grateful to @larvol for the inclusion. @ascocancer.bsky.social
Can a shingles vaccine protect the brain?
Zoster vaccination linked to a 20% lower risk of dementia over 7 years.
@nature.com
rdcu.be/egydp
Zoster vaccination linked to a 20% lower risk of dementia over 7 years.
@nature.com
rdcu.be/egydp
April 6, 2025 at 4:21 PM
Can a shingles vaccine protect the brain?
Zoster vaccination linked to a 20% lower risk of dementia over 7 years.
@nature.com
rdcu.be/egydp
Zoster vaccination linked to a 20% lower risk of dementia over 7 years.
@nature.com
rdcu.be/egydp
TIL therapy + pembrolizumab (SEL-TIL + P) shows 23.5% response in mismatch repair–proficient GI cancers—where immunotherapy usually fails.
Neoantigen recognition may be the key.
@oncoalert.bsky.social @nature.com @viveksubbiah.bsky.social @jameabraham.bsky.social
Neoantigen recognition may be the key.
@oncoalert.bsky.social @nature.com @viveksubbiah.bsky.social @jameabraham.bsky.social
April 6, 2025 at 4:10 PM
TIL therapy + pembrolizumab (SEL-TIL + P) shows 23.5% response in mismatch repair–proficient GI cancers—where immunotherapy usually fails.
Neoantigen recognition may be the key.
@oncoalert.bsky.social @nature.com @viveksubbiah.bsky.social @jameabraham.bsky.social
Neoantigen recognition may be the key.
@oncoalert.bsky.social @nature.com @viveksubbiah.bsky.social @jameabraham.bsky.social
Next-gen precision oncology in action.
OncoIncytes: visualizing PD-L1 & HER2 expression in CTCs—
real-time mutation tracking.
From slides to survival.
The future is cell-deep.
#LiquidBiopsy #CancerResearch
@oncoalert.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social
OncoIncytes: visualizing PD-L1 & HER2 expression in CTCs—
real-time mutation tracking.
From slides to survival.
The future is cell-deep.
#LiquidBiopsy #CancerResearch
@oncoalert.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social
April 6, 2025 at 5:24 AM
Next-gen precision oncology in action.
OncoIncytes: visualizing PD-L1 & HER2 expression in CTCs—
real-time mutation tracking.
From slides to survival.
The future is cell-deep.
#LiquidBiopsy #CancerResearch
@oncoalert.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social
OncoIncytes: visualizing PD-L1 & HER2 expression in CTCs—
real-time mutation tracking.
From slides to survival.
The future is cell-deep.
#LiquidBiopsy #CancerResearch
@oncoalert.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social